Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies.
Reports of a possible correlation between anti-Scl-70 antibody concentration and clinical manifestations in systemic sclerosis patients have recently appeared in the scientific literature. The goal of our study was to evaluate, by means of a multicenter study, the analytical reliability of immunoassay systems in the quantitative measurement of Scl-70 antibodies. Three blind samples (H, M, L) at different anti-Scl-70 antibody concentrations, and a low concentration antibody serum (LPC) used as a common calibrator, were sent three times in a 6-month time span to 39 Italian clinical laboratories. Each laboratory was asked to calculate dosages following the enzyme-linked immunosorbent assay (ELISA) method they used and report the optical density values of each sample (ODs), of the cutoff serum provided by the manufacturer of the kit used (ODco) and of LPC (ODLPC). The overall analytical imprecision (between methods and between laboratories) of the three different determinations of the values respectively expressed in ODs, ODs/ODco and ODs/ODLPCratio was 47.1, 52.8 and 34.0% for sample H, 56.2, 47.4% and 34% for sample M and 84.6, 86.0 and 86.6% for sample L. The average intra-method analytical imprecision was, respectively, 20.7, 29.8 and 18.6% for sample H, 24.6, 26.5 and 19.3% for sample M, and 30.6, 28.1 and 20.2% for sample L. The commercial ELISA methods currently used to determine the presence of anti-Scl-70 autoantibodies show considerable differences in the quantitative determination. The best results for reproducibility analyses have been obtained when the values were expressed as a ratio between the ODs of the sample and of the common calibrator (ODs/ODLPC). Forward-looking clinical studies that can clarify the usefulness of quantitative determination of anti-Scl-70 antibodies in the monitoring of diffuse scleroderma patients can be performed only when standard serum with a known antibody concentration and calibration curves for quantitative ELISA measurements are made available.
Villalta
D
D
Immunologia Clinica e Virologia, A.O. S. Maria degli Angeli, Pordenone, Italy.
Bizzaro
N
N
Platzgummer
S
S
Antico
A
A
Tampoia
M
M
Camogliano
L
L
Bassetti
D
D
Pradella
M
M
Piazza
A
A
Manoni
F
F
Tozzoli
R
R
Tonutti
E
E
D001323:Autoantibodies / Q000032:analysis*; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D004264:DNA Topoisomerases, Type I; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D007558:Italy; D009687:Nuclear Proteins / Q000032:analysis*; D011237:Predictive Value of Tests; D011933:Reagent Kits, Diagnostic; D015203:Reproducibility of Results; D013223:Statistics as Topic
D001323:Autoantibodies; D015415:Biomarkers; D009687:Nuclear Proteins; D011933:Reagent Kits, Diagnostic; C048100:Scl 70 antigen, human; D004264:DNA Topoisomerases, Type I